PL380169A1 - Dostarczenie aktywnego leku do części tylnej oka poprzez podspojówkowe albo okołogałkowe dostarczenie proleku - Google Patents
Dostarczenie aktywnego leku do części tylnej oka poprzez podspojówkowe albo okołogałkowe dostarczenie prolekuInfo
- Publication number
- PL380169A1 PL380169A1 PL380169A PL38016904A PL380169A1 PL 380169 A1 PL380169 A1 PL 380169A1 PL 380169 A PL380169 A PL 380169A PL 38016904 A PL38016904 A PL 38016904A PL 380169 A1 PL380169 A1 PL 380169A1
- Authority
- PL
- Poland
- Prior art keywords
- delivery
- prodrug
- periocular
- drug via
- polymeric microparticle
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000011859 microparticle Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/617,468 US20050009910A1 (en) | 2003-07-10 | 2003-07-10 | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
| PCT/US2004/021938 WO2005011741A2 (en) | 2003-07-10 | 2004-07-07 | Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL380169A1 true PL380169A1 (pl) | 2007-01-08 |
Family
ID=33564972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL380169A PL380169A1 (pl) | 2003-07-10 | 2004-07-07 | Dostarczenie aktywnego leku do części tylnej oka poprzez podspojówkowe albo okołogałkowe dostarczenie proleku |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20050009910A1 (pl) |
| EP (1) | EP1644047A2 (pl) |
| JP (1) | JP2007528851A (pl) |
| KR (1) | KR20060033008A (pl) |
| CN (1) | CN1882362A (pl) |
| AU (1) | AU2004260645B2 (pl) |
| BR (1) | BRPI0412496A (pl) |
| CA (1) | CA2531753A1 (pl) |
| IL (1) | IL172583A (pl) |
| MX (1) | MXPA06000408A (pl) |
| NO (1) | NO20056174L (pl) |
| NZ (2) | NZ582376A (pl) |
| PL (1) | PL380169A1 (pl) |
| RU (1) | RU2353393C2 (pl) |
| WO (1) | WO2005011741A2 (pl) |
| ZA (1) | ZA200510129B (pl) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| CA2549161A1 (en) * | 2003-12-02 | 2005-06-23 | Allergan, Inc. | Prevention and/or reduction of photoreceptor degeneration with retinoids |
| US8871224B2 (en) | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| JP2007529434A (ja) | 2004-03-17 | 2007-10-25 | ラース マイケル ラーセン， | 視覚サイクルの阻害による網膜症の予防 |
| US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
| AU2011211380B9 (en) * | 2004-04-30 | 2014-05-08 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitor implants |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| WO2006043965A1 (en) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US8246949B2 (en) * | 2004-10-27 | 2012-08-21 | Aciont, Inc. | Methods and devices for sustained in-vivo release of an active agent |
| PL1959925T3 (pl) * | 2005-12-02 | 2017-05-31 | (Osi) Eyetech, Inc. | Mikrocząstki o kontrolowanym uwalnianiu |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US8197435B2 (en) * | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
| CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
| SI1864668T1 (sl) * | 2006-06-01 | 2013-04-30 | Novagali Pharma S.A. | Uporaba predzdravil za okularno intravitrealno dajanje |
| EP2432453A2 (en) | 2009-05-20 | 2012-03-28 | Ranbaxy Laboratories Limited | Topical retinoid solutions |
| US10022348B2 (en) | 2009-05-20 | 2018-07-17 | Sun Pharmaceutical Industries Limited | Topical solution of isotretinoin |
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| CN106214321B (zh) | 2010-10-15 | 2018-08-28 | 科尼尔赛德生物医学公司 | 用于进入眼睛的装置 |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| CA2863632C (en) | 2012-01-19 | 2017-07-11 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| CN104363924B (zh) | 2012-03-16 | 2018-04-17 | 约翰霍普金斯大学 | 用于递送hif‑1抑制剂的控制释放调配物 |
| JP6138904B2 (ja) | 2012-03-16 | 2017-05-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9056057B2 (en) | 2012-05-03 | 2015-06-16 | Kala Pharmaceuticals, Inc. | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| EP2844227B1 (en) | 2012-05-03 | 2020-11-18 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| JP6392209B2 (ja) | 2012-05-04 | 2018-09-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
| EA034963B1 (ru) | 2012-11-08 | 2020-04-13 | Клиасайд Байомедикал, Инк. | Способ лечения расстройства заднего сегмента глаза |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CN105246529B (zh) | 2013-05-03 | 2019-06-14 | 科尼尔赛德生物医学公司 | 用于眼部注射的设备和方法 |
| WO2014197317A1 (en) | 2013-06-03 | 2014-12-11 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
| US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
| EP3099290A1 (en) | 2014-01-28 | 2016-12-07 | Allergan, Inc. | Topical retinoid formulations and methods of use |
| WO2015127389A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic enema formulations and methods of use |
| EP3157598A4 (en) | 2014-06-20 | 2018-05-16 | Clearside Biomedical, Inc. | Variable diameter cannula and methods for controlling insertion depth for medicament delivery |
| EP3250184B1 (en) | 2015-01-27 | 2024-12-18 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| US10390901B2 (en) | 2016-02-10 | 2019-08-27 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
| JP2019514581A (ja) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル，インコーポレイテッド | 眼の薬物送達のためのシステムおよび方法 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| KR20190036520A (ko) | 2016-06-27 | 2019-04-04 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물 |
| WO2018005860A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| CN110177527B (zh) | 2016-08-12 | 2022-02-01 | 科尼尔赛德生物医学公司 | 用于调节药剂递送用针的插入深度的装置和方法 |
| AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| US12090294B2 (en) | 2017-05-02 | 2024-09-17 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| TW201906635A (zh) * | 2017-07-04 | 2019-02-16 | 日商第一三共股份有限公司 | 伴隨視細胞變性的視網膜變性的疾病用藥 |
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| EP3841086B1 (en) | 2018-08-20 | 2025-04-23 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| JP7504088B2 (ja) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | 医学的障害の治療のための一酸化炭素プロドラッグ |
| WO2020210805A1 (en) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| JP2023515073A (ja) | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |
| MX2022010952A (es) | 2020-03-05 | 2022-10-07 | C4 Therapeutics Inc | Compuestos para la degradacion dirigida de brd9. |
| MX2022014573A (es) | 2020-05-19 | 2022-12-15 | G1 Therapeutics Inc | Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos. |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5275820A (en) * | 1990-12-27 | 1994-01-04 | Allergan, Inc. | Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles |
| US5384333A (en) * | 1992-03-17 | 1995-01-24 | University Of Miami | Biodegradable injectable drug delivery polymer |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5420120A (en) * | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
| NZ283658A (en) * | 1994-04-04 | 1999-09-29 | William R Freeman | Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides) |
| CA2187353C (en) * | 1994-04-08 | 2007-05-22 | Gerald L. Yewey | Liquid delivery compositions |
| US5824685A (en) * | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| US5718922A (en) * | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
| US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| IL140899A0 (en) * | 1998-07-17 | 2002-02-10 | Skyepharma Inc | Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof |
| US6017938A (en) * | 1998-07-28 | 2000-01-25 | Bershad; Susan | Short contact treatment for acne |
| US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| US6489335B2 (en) * | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| US20040142475A1 (en) * | 2000-06-02 | 2004-07-22 | Barman Shikha P. | Delivery systems for bioactive agents |
| AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
| JP4061015B2 (ja) * | 2000-10-30 | 2008-03-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レチノイン酸レセプターアゴニスト作用を有する薬剤含有組成物 |
| US6673802B2 (en) * | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| EP2283845A1 (en) * | 2001-04-26 | 2011-02-16 | pSivida Inc. | Sustained release drug delivery system containing codrugs |
| GB0122318D0 (en) * | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7381426B2 (en) * | 2002-01-24 | 2008-06-03 | Southwest Research Institute | Targeted delivery of bioactive factors to the systemic skeleton |
| US20050143363A1 (en) * | 2002-09-29 | 2005-06-30 | Innorx, Inc. | Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases |
-
2003
- 2003-07-10 US US10/617,468 patent/US20050009910A1/en not_active Abandoned
-
2004
- 2004-07-07 NZ NZ582376A patent/NZ582376A/en not_active IP Right Cessation
- 2004-07-07 MX MXPA06000408A patent/MXPA06000408A/es unknown
- 2004-07-07 BR BRPI0412496-0A patent/BRPI0412496A/pt not_active IP Right Cessation
- 2004-07-07 CA CA002531753A patent/CA2531753A1/en not_active Abandoned
- 2004-07-07 AU AU2004260645A patent/AU2004260645B2/en not_active Ceased
- 2004-07-07 KR KR1020067000591A patent/KR20060033008A/ko not_active Ceased
- 2004-07-07 JP JP2006518912A patent/JP2007528851A/ja active Pending
- 2004-07-07 NZ NZ544027A patent/NZ544027A/en not_active IP Right Cessation
- 2004-07-07 WO PCT/US2004/021938 patent/WO2005011741A2/en not_active Ceased
- 2004-07-07 RU RU2006104983/14A patent/RU2353393C2/ru not_active IP Right Cessation
- 2004-07-07 CN CNA2004800195540A patent/CN1882362A/zh active Pending
- 2004-07-07 PL PL380169A patent/PL380169A1/pl not_active Application Discontinuation
- 2004-07-07 EP EP04777796A patent/EP1644047A2/en not_active Withdrawn
-
2005
- 2005-12-13 ZA ZA200510129A patent/ZA200510129B/en unknown
- 2005-12-14 IL IL172583A patent/IL172583A/en not_active IP Right Cessation
- 2005-12-23 NO NO20056174A patent/NO20056174L/no not_active Application Discontinuation
-
2012
- 2012-02-29 US US13/407,906 patent/US20120157499A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20056174L (no) | 2006-01-25 |
| CA2531753A1 (en) | 2005-02-10 |
| IL172583A0 (en) | 2006-04-10 |
| RU2006104983A (ru) | 2006-06-27 |
| AU2004260645B2 (en) | 2010-03-11 |
| US20120157499A1 (en) | 2012-06-21 |
| IL172583A (en) | 2011-02-28 |
| ZA200510129B (en) | 2007-02-28 |
| JP2007528851A (ja) | 2007-10-18 |
| BRPI0412496A (pt) | 2006-09-19 |
| EP1644047A2 (en) | 2006-04-12 |
| AU2004260645A1 (en) | 2005-02-10 |
| MXPA06000408A (es) | 2006-03-17 |
| WO2005011741A3 (en) | 2005-04-14 |
| US20050009910A1 (en) | 2005-01-13 |
| CN1882362A (zh) | 2006-12-20 |
| KR20060033008A (ko) | 2006-04-18 |
| RU2353393C2 (ru) | 2009-04-27 |
| NZ582376A (en) | 2012-02-24 |
| WO2005011741A2 (en) | 2005-02-10 |
| NZ544027A (en) | 2010-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL380169A1 (pl) | Dostarczenie aktywnego leku do części tylnej oka poprzez podspojówkowe albo okołogałkowe dostarczenie proleku | |
| IL174690A0 (en) | Enhanced drug delivery | |
| GB0310300D0 (en) | Nanocomposite drug delivery composition | |
| EP1691826A4 (en) | EXCIPIENTS IN MEDICINE DELIVERY VEHICLES | |
| EP1691785A4 (en) | EXCIPIENTS FOR TRANSPORTING DRUGS | |
| SI1635875T1 (sl) | Sistem za dajanje zdravila, ki se gelira in situ | |
| PL1631255T3 (pl) | System dostarczania leków | |
| AU2003266133A8 (en) | Materials and methods for drug delivery and uptake | |
| IL170060A (en) | Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems | |
| EP1601836A4 (en) | ASPHALT SPREADING AND COMPACTION SYSTEM | |
| PT2260892E (pt) | Bombas de fornecimento de fármaco implantáveis multidepósito | |
| IL172223A0 (en) | Drug delivery systems for tumor targeting ngr-molecules and uses thereof | |
| PL1824460T3 (pl) | Stabilizowany polimerowy układ dostarczania | |
| GB0605772D0 (en) | Drug delivery system | |
| GB2400565B (en) | Nasal drug delivery | |
| AP2006003602A0 (en) | Oral drug delivery system | |
| AU2003212962A8 (en) | Transdermal drug delivery systems | |
| AU2003272127A1 (en) | Polymeric composition for drug delivery | |
| HK1089111A (en) | Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle | |
| EP1696886A4 (en) | METHODS AND COMPOSITIONS FOR DELIVERY OF DRUGS | |
| EP1620077A4 (en) | ORAL DRUG DELIVERY SYSTEM HAVING ENHANCED PROLONGED RELEASE | |
| GB0327814D0 (en) | Aerosolisable composition and delivery system | |
| GB0311084D0 (en) | Drug delivery | |
| GB0329141D0 (en) | Drug delivery | |
| GB0401008D0 (en) | Drug delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |